Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951705 | 0.88 | MAPT (0.33) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2204036 | 0.79 | CA2 (0.41) | SIGMAR1KMT2ASMN1; SMN2 | |
| SCHEMBL2201870 | 0.79 | KMT2A (0.35) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4951701 | 0.71 | KMT2A (0.37) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2201877 | 0.69 | SMN1; SMN2 (0.45) | SIGMAR1MAPTNPSR1KMT2ALMNA | |
| SCHEMBL4947147 | 0.66 | CA2 (0.40) | SIGMAR1MAPTNPSR1POLBKMT2A | |
| SCHEMBL12426462 | 0.65 | KMT2A (0.45) | MAPTKMT2ALMNA | |
| SCHEMBL7573468 | 0.61 | MAPT (0.41) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7573472 | 0.61 | MAPT (0.41) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14613958 | 0.59 | GRIN2D (0.55) | MAPTGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | SIGMAR1 180/4885MAPT 4530/4885GRIN2D 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.